Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Director dealings: Berkeley CEO raises stake

(Sharecast News) - Berkeley revealed on Tuesday that chief executive Robert Perrins had acquired 2,816 ordinary shares in the FTSE 100-listed property developer. Perrins, who joined Berkeley in 1994, purchased the shares at an average price of 3,550.0p each, for a total value of £99,968.

As of 1525 BST, Berkeley shares were up 0.11% at 3,664.0p.

Reporting by Iain Gilbert at Sharecast.com

Top Director Buys

Brave Bison Group (BBSN) Director name: Green,Oliver Amount purchased: 714,285 @ 49.00p Value: £349,999.66

Zigup (ZIG) Director name: Ward,Martin Amount purchased: 49,369 @ 329.00p Value: £162,424.01

Berkeley Group Holdings (the) (BKG) Director name: Perrins,Robert C G Amount purchased: 2,816 @ 3,550.00p Value: £99,968.00

Top Director Sells

Frontier Developments (FDEV) Director name: Braben ,David John Amount sold: 5,000 @ 362.50p Value: £18,125.00

Share this article

Related Sharecast Articles

Director dealings: Essentra CEO raises stake
(Sharecast News) - Essentra revealed on Wednesday that chief execuitve Scott Fawcett had acquired 17,483 ordinary shares in the FTSE 250-listed hardware manufacturer.
Director dealings: AB Dynamics CEO snaps up shares
(Sharecast News) - AB Dynamics revealed on Tuesday that chief executive Sarah Matthews-DeMers had acquired 2,000 ordinar shares in the AIM-listed automotive testing and development solution supplier.
Director dealings: Bioventix chairman raises stake
(Sharecast News) - Bioventix revealed on Monday that chairman Ian Nicholson had acquired 1,000 ordinary shares in the AIM-listed biotechnology firm.
Director dealings: Bioventix chairman raises stake
(Sharecast News) - Bioventix revealed on Monday that chairman Ian Nicholson had acquired 1,000 ordinary shares in the AIM-listed biotechnology firm.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.